Innovative Medicines & Omics (IMO) is a peer-reviewed, open-access journal dedicated to advancing the discovery and development of innovative medicines through cutting-edge omics research in human and animal health.

The journal provides a premier platform for researchers, clinicians, and industry scientists to disseminate high-quality original research, reviews, and short communications. By integrating diverse omics layers—including genomics, proteomics, epigenomics, metabolomics, lipidomics, metagenomics, pharmacogenomics, and toxicogenomics—IMO aims to bridge the gap between molecular insights and clinical applications.

Our scope encompasses all major therapeutic areas, with a particular focus on disease etiology, prevention, treatment, prognosis, and monitoring. Key topics include single-cell sequencing, circulating tumor cells, personalized medicine, drug sensitivity screening, novel therapeutic targets, drug delivery, and computational biology.

To ensure the highest academic standards, all substantive manuscripts undergo rigorous double-blind peer review. IMO is committed to fostering global scientific collaboration and translating multi-omics discoveries into tangible therapeutic innovations for both human and veterinary medicine.